期刊
CHEMBIOCHEM
卷 23, 期 2, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cbic.202100270
关键词
PROTAC; E3; mechanistic and kinetic studies; pharmacokinetic; resistance
资金
- NIH funding from the NCI [R35 CA197589]
PROTACs are an emerging technology that utilizes the ubiquitin-proteasome system for targeted protein degradation, showing great therapeutic potential in treating diseases. Over the past two decades, significant advancements have been made in PROTAC technology, with an increasing repertoire of targets.
Proteolysis-targeting chimeras (PROTACs), an emerging paradigm-shifting technology, hijacks the ubiquitin-proteasome system for targeted protein degradation. PROTACs induce ternary complexes between an E3 ligase and POI, and this induced proximity leads to polyUb chain formation on substrates and eventual proteasomal-mediated POI degradation. PROTACs have shown great therapeutic potential by degrading many disease-causing proteins, such as the androgen receptor and BRD4. The PROTAC technology has advanced significantly in the last two decades, with the repertoire of PROTAC targets increased tremendously. Herein, we describe recent developments of PROTAC technology, focusing on mechanistic and kinetic studies, pharmacokinetic study, spatiotemporal control of PROTACs, covalent PROTACs, resistance to PROTACs, and new E3 ligands.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据